Sirohi Bhawna, Barreto Savio George, Patkar Shraddha, Gupta Alok, DeSouza Ashwin, Talole Sanjay, Deodhar Kedar, Shetty Nitin, Engineer Reena, Goel Mahesh, Shrikhande Shailesh V
Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India.
Department of Gastrointestinal and Hepato-Pancreato-Biliary Surgical Oncology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India.
Indian J Med Paediatr Oncol. 2014 Oct;35(4):263-6. doi: 10.4103/0971-5851.144986.
Neoadjuvant chemoradiotherapy (NACTRT) improves local recurrence rate in locally advanced (LA) rectal cancer with no survival benefit. Pathological complete response (pCR) post-NACTRT is associated with improved outcome. Debate is ongoing as to when would be the opportune time to operate.
To determine if greater down-staging can be achieved by a longer time interval from NACTRT to surgery (tumor regression score [TRS]) and whether this would impact sphincter saving surgery rates and early relapse rates.
A retrospective analysis of a prospectively maintained database of patients with LA rectal adenocarcinoma treated from January 2012 to August 2013 was carried out. One hundred and ten patients who completed NACTRT (50 Gy/25 fractions with capecitabine 825 mg/m(2) twice daily) followed by surgical resection were included. For response evaluation patients were divided into two groups, Group 1 (TRS ≤60 days, n = 42) and 2 (TRS >60 days, n = 68). Tumor down-staging, pCR rate, tumor regression grade (TRG) post-NACTRT and relapse rates were correlated with TRS.
Of 110 patients (median age: 49 years (21-73), 71% males; 18 (16.5%) with signet ring histology) 96% patients underwent an R0 resection. Post-NACTRT, CR was attained in 5 (4.5%), partial response in 98 (89%) and stable disease in 7 (6.4%) patients. Median time from completion of NACTRT to surgery was 64.5 days (6-474). Median lymph nodes harvested were 10 (1-50). Overall, 22 (20%) patients achieved pCR. 26 (62%) patients in Group 1 compared to 36 (53%) in Group 2 underwent sphincter sparing surgery (SSS) (P = 0.357). Six patients (14%) in Group 1 and 16 (24%) in Group 2 achieved pCR (P = 0.24). Median TRG in both groups was three.
Timing of surgery following NACTRT for LA rectal cancer does not influence pathological response, ability to perform SSS or disease-free survival. There is no incremental benefit of delaying the surgery though this needs to be confirmed in a prospective randomized trial.
新辅助放化疗(NACTRT)可提高局部晚期(LA)直肠癌的局部复发率,但对生存率无益处。NACTRT后的病理完全缓解(pCR)与预后改善相关。关于何时是手术的最佳时机仍在争论中。
确定从NACTRT到手术的时间间隔更长(肿瘤退缩评分[TRS])是否能实现更大程度的降期,以及这是否会影响保肛手术率和早期复发率。
对2012年1月至2013年8月接受治疗的LA直肠腺癌患者的前瞻性维护数据库进行回顾性分析。纳入110例完成NACTRT(50 Gy/25次分割,卡培他滨825 mg/m²,每日两次)后接受手术切除的患者。为进行反应评估,将患者分为两组,第1组(TRS≤60天,n = 42)和第2组(TRS>60天,n = 68)。肿瘤降期、pCR率、NACTRT后的肿瘤退缩分级(TRG)和复发率与TRS相关。
110例患者(中位年龄:49岁[21 - 73岁],71%为男性;18例[16.5%]为印戒细胞组织学类型)中,96%的患者接受了R0切除。NACTRT后,5例(4.5%)达到完全缓解(CR),98例(89%)部分缓解,7例(6.4%)疾病稳定。从完成NACTRT到手术的中位时间为64.5天(6 - 474天)。中位切除淋巴结数为10个(1 - 50个)。总体而言,22例(20%)患者实现了pCR。第1组26例(62%)患者与第2组36例(53%)患者接受了保肛手术(SSS)(P = 0.357)。第1组6例(14%)患者和第2组16例(24%)患者实现了pCR(P = 0.24)。两组的中位TRG均为3级。
LA直肠癌NACTRT后的手术时机不影响病理反应、进行SSS的能力或无病生存期。延迟手术没有额外益处,不过这需要在前瞻性随机试验中得到证实。